GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AngioLab Inc (XKRX:251280) » Definitions » Minority Interest

AngioLab (XKRX:251280) Minority Interest : ₩0.00 Mil (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is AngioLab Minority Interest?

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

AngioLab's minority interest for the quarter that ended in Dec. 2023 was ₩0.00 Mil.


AngioLab Minority Interest Historical Data

The historical data trend for AngioLab's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AngioLab Minority Interest Chart

AngioLab Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Minority Interest
Get a 7-Day Free Trial - - - - -

AngioLab Semi-Annual Data
Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Minority Interest Get a 7-Day Free Trial - - - - -

AngioLab Minority Interest Calculation

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.


AngioLab (XKRX:251280) Business Description

Traded in Other Exchanges
N/A
Address
65 Techno 3ro, Suite 159, Hanshin S Mecca, Yuseong-gu, Doejeon, CHN
AngioLab Inc is a biotechnology company. It develops products based on angiogenesis inhibitors. It discovers, develops, and markets anti-angiogenic candidates to inhibit the abnormal growth of new blood vessel.

AngioLab (XKRX:251280) Headlines

No Headlines